Smith & Nephew, Zimmer Biomet, Medovex & more: 20 key notes

Spinal Tech

Here are 20 key notes on orthopedic and spine device companies over the past week.

Active Implants' VENUS clinical trial is now underway at Duke University Medical Center in Durham, N.C.

 

Active Implants initiated its second clinical trial for the investigational NUsurface meniscus implant.

 

Amendia developed the OmegaLIF expandable lumbar interbody device for intervertebral body spinal fusion procedures.

 

Bone Therapeutics extended its collaboration with Kasios, a synthetic bone substitute specialist.


 
BONESUPPORT's CERAMENT|G registry now includes 230 cases.

 

CollPlant reported positive final clinical trial results for Vergenix STR.

 

Episurf Medical's proprietary μifidelity platform has been used in 100 cases.


 
Exactech acquired its independent distribution partner Exactech Australia.


 
Germany released new reimbursement payment coding for Medovex's DenerveX Facet Joint Syndrome Treatment.

 

Medtech sold two ROSA Brain robots in the United States.

 

Merete Technologies' PediatrOS RigidTack and FlexTack novel epiphysiodesis staples have received FDA 510(k) clearance.

 

Osiris Therapeutics announced a number of leadership changes, including the appointment of Dwayne Montgomery, its current chief business officer, as interim CEO.

 

All eight Medicare Administrative Contractors have confirmed coverage for the treatment of chronic wounds with Osiris Therapeutics' Grafix.

 

OSSim Technologies is continuing its expansion by adding neurosurgery and spine surgery to its list of surgical simulators.


 
Smith & Nephew CEO Olivier Bohuon was diagnosed with cancer.


 
Smith & Nephew's fourth quarter revenue climbed 5 percent from the same period last year to reach $1.24 billion.

 

Moody's Investors Service placed Stryker's A3 unsecured note ratings on review for downgrade, on the heels of the news that Stryker plans to acquire Sage Products for approximately $2.7 billion.

 

Stryker acquired Sage Products from Madison Dearborn Partners for $2.7 billion.


 
TranS1 named Chris Groppa as chief marketing officer and director of reimbursement.

 

Zimmer Biomet net sales in the Americas were up 41.2 percent in 2015 to $3.6 billion.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers